TRPV4 and cancer: Subsequently, we administered vehicle or different doses of a highly selective TRPV4 antagonist, GSK2193874 (2.5, 25, and 250 μg), into the cancer model, and measured the effect on oral cancer-induced mechanical allodynia and thermal hypersensitivity.